| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
LiquidSEQ™
Test CodeLIQSEQ or 14308
CPT Codes
81464
Preferred Specimen
10 mL whole blood collected in each of two separate Streck cell-free DNA blood collection tubes
Minimum Volume
10 mL
Instructions
This test requires two Streck tubes. Blood will be collected in office via LiquidSEQ™ Kit for in office and in home draws. Specimens may be shipped separately and at different times. Do not hold blood specimen due to short stability. Do not reject.
Blood collection using a straight needle is preferred. All tubes must be filled completely. Gently invert tube at least 8 times immediately after draw.
If blood collection is not available in office and providers would like to utilize an in-home draw for blood collection, a mail to home LiquidSEQ kit should be ordered. Simply add test code 13676, "Mobile Phlebotomy Collection, Precision Oncology" with an in-home draw service add test code 18645, “LiquidSEQ kit", to any order containing LiquidSEQ testing.
Please note: If an in-home draw is involved, a collection kit will be shipped to the patient.
Please note: The LiquidSEQ kit is not required for PSC draws.
Blood collection using a straight needle is preferred. All tubes must be filled completely. Gently invert tube at least 8 times immediately after draw.
If blood collection is not available in office and providers would like to utilize an in-home draw for blood collection, a mail to home LiquidSEQ kit should be ordered. Simply add test code 13676, "Mobile Phlebotomy Collection, Precision Oncology" with an in-home draw service add test code 18645, “LiquidSEQ kit", to any order containing LiquidSEQ testing.
Please note: If an in-home draw is involved, a collection kit will be shipped to the patient.
Please note: The LiquidSEQ kit is not required for PSC draws.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: Unacceptable
Frozen: Unacceptable
Refrigerated: Unacceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Do not reject, send to laboratory for testing assessment
Methodology
Next Generation Sequencing
Setup Schedule
Sun, Tues, Thurs
Report Available
7-10 days
Limitations
**This test is not available for New York and Wyoming patient testing**
Reference Range
See Laboratory Report
Clinical Significance
The 523-gene comprehensive genomic profiling panel is intended to help oncologists deliver precision medicine by providing personalized genomic analysis of a patient’s blood. This comprehensive panel offers the opportunity for a broader scope of genomic information compared to single gene tests or smaller panels and an alternative specimen type for comprehensive genomic profiling of a patient’s solid tumor. For example, it may be useful for patients with limited or ill-defined treatment options and for those considering clinical trials in the event tumor tissue is not available or insufficient for tissue-based testing. This panel uses next-generation sequencing to detect mutations present in circulating tumor DNA (ctDNA) extracted from a solid tumor patient’s blood plasma. The test is designed to detect single nucleotide variants (SNVs) and small insertions/deletions, as well as whole-gene copy number alterations and translocations in a select group of genes. Microsatellite instability (MSI) and tumor mutation burden (TMB) are also evaluated.
Performing Laboratory
med fusion
